Pfizer

On an ordinary day over the last month of trading, PFE has moved about 1.21%, making it a little calmer than most of the stocks Kinzan tracks (their median is 1.81%).

Measured against its own habit, today is a −1.1σ day: the kind it has roughly once a week.

It sits in the lower half of its 24-hour range of 29.85–30.44, measured on hourly closes.

Most of the move came in the New York session (13:00–22:00 UTC), which accounted for about 59% of the day's price action.

Over the last 60 sessions of daily returns, it has moved most closely with MRK (+0.65, a strong relationship).

Its last close is at the 99th percentile of its own last 82 sessions, and its 20-day volatility at the 42nd.

Market read: Pfizer is drifting lower, failing to recover from a weak New York session performance.

What it is

Pfizer, founded in New York in 1849, has narrowed itself over the past decade into a company that sells only innovative medicines and vaccines. It combined its off-patent generics unit with Mylan to form Viatris, and its consumer-health products went into a joint venture with GSK that was later listed as Haleon. What remains spans vaccines, including a long-standing pneumococcal franchise; oncology, which it expanded through acquisition into antibody-drug conjugates that deliver chemotherapy directly to cancer cells; cardiovascular and internal medicine, including an anticoagulant marketed in alliance with Bristol Myers Squibb; inflammation and immunology; and rare diseases. During the pandemic it developed a covid vaccine with BioNTech and an oral antiviral, which for a short period made it one of the highest-revenue drugmakers in the world.

What drives it

The shares spent several years unwinding that pandemic surge. Covid sales fell steeply as demand normalised, and earnings were reset lower. The next challenge was already visible behind it: several of its larger medicines lose exclusivity in the second half of this decade, so the investment case rests on whether newer products and acquired pipelines can replace that revenue in time. The company has paired that effort with cost-reduction programmes. The dividend is a large part of why people own the shares, and its coverage by earnings is a recurring question whenever guidance is cut. US policy matters on two fronts, drug-price negotiation under Medicare and the direction of federal vaccine recommendations, which shape demand for a business where vaccines are an unusually large share.

How it trades through the day

It has a very large number of shares in issue and trades in heavy volume, with modest daily percentage moves. Results are released before the US open, and the cash session runs 13:30 to 20:00 UTC in the northern summer and 14:30 to 21:00 UTC in winter. Vaccine advisory meetings and regulatory decisions follow their own calendar.

What it tends to move with

It trades with the large US drugmakers, Merck, Bristol Myers Squibb and Johnson & Johnson. Its link to BioNTech and Moderna, strong during the pandemic, has weakened as covid revenue has shrunk. As an income share it sometimes moves with other high-dividend value names, and can respond to bond yields in the same way.